|Table of Contents|

Efficacy and safety of camrelizumab combined with albumin paclitaxel in second-line treatment of advanced gastric cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 01
Page:
130-134
Research Field:
Publishing date:

Info

Title:
Efficacy and safety of camrelizumab combined with albumin paclitaxel in second-line treatment of advanced gastric cancer
Author(s):
XU Zeyu; WANG Haiyan; TIAN Yuan
Department of Medical Oncology,the Affiliated Hospital of Xuzhou Medical University,Jiangsu Xuzhou 221002,China.
Keywords:
advanced gastric cancer; camrelizumab; abraxane; apatinib; efficacy
PACS:
R735.2
DOI:
10.3969/j.issn.1672-4992.2023.01.024
Abstract:
Objective:To evaluate the efficacy and adverse effects of camrelizumab combined with albumin bound paclitaxel(abraxane) of second-line treatment for advanced gastric cancer,and further explore the benefit population.Methods:Patients with locally advanced/distant metastatic gastric cancer in our hospital from June 2019 to May 2021，and progression of first-line chemotherapy were treated with L-OHP+capecitabine/S-1.All 112 patients was randomly divided into two groups,study group of 55 cases(camrelizumab combined abraxane),control group 57 cases(abraxane combined apatinib).Efficacy was evaluated using the RECIST criteria and(NCI-CTCAE) 4.0 criteria and adverse reactions,respectively.Survival analysis was performed using the Kaplan-Meier and COX regression analysis.Results:ORR(objective response rate) were 45.5% and 26.3%,DCR(disease control rate） were 76.4% and 57.9%(P＜0.05),mPFS(median progression-free survival) were 5.6 and 4.4 months(P＜0.05),mOS(median overall survival) were 13.1 and 11.6 months(P＜0.05) in the study and control groups.ECOG=0，EBV positive,PD-L1 CPS ≥5，were more significant and statistically significant in study group(P＜0.05).In terms of safety,the main grade 2 adverse reactions were leukocytopia,digestive tract reaction,RCCEP,hypertension,immune adverse reactions,no fatal AE.Conclusion:Second-line treatment of camrelizumab and abraxane can significantly prolong PFS and OS，and toxic response can be in control.It is also excellent for patients after second-line therapy.

References:

［1］THRIFT AARON P,NGUYEN THERESA H.Gastric cancer epidemiology［J］.Gastrointestinal Endoscopy Clinics of North America,2021,31(3)：425-439.
［2］WANG FH,ZHANG XT,LI YF,et al.The Chinese Society of Clinical Oncology(CSCO):Clinical guidelines for the diagnosis and treatment of gastric cancer,2021［J］.Cancer Communications,2021,41(8):747-795.
［3］SHIMIZU KENJI,SUGIURA DAISUKE,OKAZAKI ILMI,et al.PD-1 preferentially inhibits the activation of low-affinity T cells［J］.Proceedings of the National Academy of Sciences of the United States of America,2021,118(35):e2107141118.
［4］JANJIGIAN YELENA Y,SHITARA KOHEI,MOEHLER MARKUS,et al.First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric,gastro-oesophageal junction,and oesophageal adenocarcinoma(CheckMate 649):a randomised,open-label,phase 3 trial［J］.The Lancet,2021,398(10294):27-40.
［5］佘明金.卡瑞利珠单抗治疗恶性肿瘤的临床研究进展［J］.癌症进展,2020,18(9):865-890,900. SHE MJ.Clinical progress of camrelizumab in the treatment of malignant tumors［J］.Cancer Progression,2020,18(9):865-890,900.
［6］YUAN M,WANG ZH,ZHANG YB,et al.Safety analysis of apatinib combined with chemotherapy in the treatment of advanced gastric carcinoma:a randomised controlled trial［J］.Journal of Oncology,2021,2021:5177140.
［7］KO CHINGCHUNG,YEH LEEREN,KUO YUTING,et al.Imaging biomarkers for evaluating tumor response:RECIST and beyond［J］.Biomarker Research,2021,9(1):52.
［8］KANG YK,BOKU N,SATOH T,et al.Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to,or intolerant of,at least two previous chemotherapy regimens(ONO-4538-12,ATTRACTION-2):a randomised,double-blind,placebo-controlled,phase 3 trial［J］.The Lancet,2017,390(10111):2461-2471.
［9］沈仕俊，甘平，王园园，等.PD-1/PD-L1通路抑制剂治疗进展期胃癌的研究进展［J］.现代肿瘤医学，2021,29（13）：2363-2368. SHEN SJ,GAN P,WANG YY,et al.Research progress of PD-1/PD-L1 pathway inhibitors in advanced gastric cancer［J］.Modern Oncology，2021,29（13）：2363-2368.
［10］N BOKU,MH RYU,K SHITARA,et al.LBA7_PR nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction(G/GEJ) cancer:ATTRACTION-4(ONO-4538-37) study［J］.Annals of Oncology,2020,31(Supl 4):S1192.
［11］张子博,刘羽,李勇,等.阿帕替尼联合其他药物治疗进展期及晚期胃癌的研究进展［J］.河北医药,2021,43(7):1082-1086. ZHANG ZB,LIU Y,LI Y,et al.Progress in the treatment of apatinib and other drugs for advanced advanced gastric cancer［J］.Hebei Medicine,2021,43(7):1082-1086.
［12］PEREIRA MA,BATISTA D,RAMOS M,et al.Epstein-barr virus positive gastric cancer:a distinct subtype candidate for immunotherapy［J］.Journal of Surgical Research,2021,261:130-138.
［13］JOSEPH CHAO,CHARLES S FUCHS,KOHEI SHITARA,et al.Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials［J］.JAMA Oncology,2021,7(6):895-902.
［14］田春艳,尹进波,许丰铭,等.阿帕替尼联合免疫调节剂治疗晚期胃癌的效果观察［J］.浙江医学,2018,40(9):996-997. TIAN CY,YIN JB,XU FM,et al.Observed the effect of apatinib combined with immunomodulator in the treatment of advanced gastric cancer［J］.Zhejiang Medicine,2018,40(9):996-997.
［15］Z LWIN,C GOMEZ-ROCA,E SAADA-BOUZID,et al.LEAP-005:Phase Ⅱ study of lenvatinib(len) plus pembrolizumab(pembro) in patients(pts) with previously treated advanced solid tumours［J］.Annals of Oncology,2020,31(Supl 4):S1170.
［16］王钎钎,郑松.抗血管生成联合免疫检查点抑制剂在晚期胃癌治疗中的研究进展［J］.浙江中西医结合杂志,2021,31(7):687-690. WANG QQ,ZHENG S.Anti-angiogenesis joint immunoassay inhibitors in the treatment of advanced gastric cancer research progress［J］.Zhejiang Journal of Chinese and Western Medicine,2021,31(7):687-690.

Memo

Memo:
-
Last Update: 2022-11-30